76742-48-8

Basic information

• Product Name: 2,2-diethoxy-ethanimidic acid methyl ester
• Synonyms: 2,2-diethoxy-ethanimidic acid methyl ester;2,2-Diethoxyacetimidic acid methyl ester;Methyl diethoxyacetimidate;Methyl 2,2-diethoxyethanimidate
• CAS NO: 76742-48-8
• Molecular Formula: C₇H₁₅NO₃
• Molecular Weight: 161.1989
• Mol File: 76742-48-8.mol

Chemical Properties

• Boiling Point: 159 °C at 760 mmHg
• Flash Point: 50 °C
• Appearance: /
• Density: 1.01 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.78±0.70(Predicted)
• CAS DataBase Reference: 2,2-diethoxy-ethanimidic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-diethoxy-ethanimidic acid methyl ester(76742-48-8)
• EPA Substance Registry System: 2,2-diethoxy-ethanimidic acid methyl ester(76742-48-8)

Safety Data

• Hazardous Substances Data: 76742-48-8(Hazardous Substances Data)

Usage

Uses

Used in Pesticide Industry:
2,2-diethoxy-ethanimidic acid methyl ester is used as an active ingredient in pesticides for its ability to control and manage various pests, thereby protecting crops and enhancing agricultural productivity.
Used as an Intermediate in Organic Synthesis:
In the chemical industry, 2,2-diethoxy-ethanimidic acid methyl ester serves as a valuable intermediate in the synthesis of a variety of organic compounds, contributing to the development of new materials and products.
Used in Pharmaceutical Industry:
2,2-diethoxy-ethanimidic acid methyl ester is utilized as a building block in the pharmaceutical sector for the production of drugs, playing a crucial role in the creation of medicinal compounds that address various health conditions.
Safety Note:
It is important to handle 2,2-diethoxy-ethanimidic acid methyl ester with care due to its harmful nature if ingested or inhaled, and its potential to cause skin and eye irritation upon contact. Proper safety measures should be implemented during its use in any application.

Upstream product

• 67-56-1 methanol 
• 6136-93-2 2,2-diethoxyacetonitrile 
• 124-41-4 sodium methylate 

Downstream Products

• 1221974-47-5 N-(2-bromo-5-fluoro-benzyl)-2,2-diethoxy-acetamidine 
• 1192814-93-9 6-methylisoquinolin-3-amine 
• 1338254-52-6 N-(2-bromo-5-chloro-benzyl)-2,2-diethoxy-acetamidine 
• 1192815-00-1 N-(3-bromo-benzyl)-2,2-diethoxy-acetamidine 
• 1338254-57-1 N-[(4-bromo-2-chloro-phenyl)methyl]-2,2-diethoxy-acetamidine 
• 1338254-39-9 N-(3-bromo-6-methoxy-benzyl)-2,2-diethoxy-acetamidine 

Relevant articles and documents

Steric interference on the redox-conjugated pyrimidine ring rotation of monoand dinuclear copper complexes with (4-Methyl-2-pyrimidinyl)imine ligands

A mononuclear copper(I) complex with N-[(4-methyl-2- pyrimidinyl)methylene] -p-toluidine (1?BF4) and a dinuclear copper(I) complex with N,N'-bis[(4-methyl-2-pyrimidinyl)- methylene]-p-phenylenediamine (2?(BF4)2) were synth

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1

This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)

MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2

The present application provides a compound of Formula: or a pharmaceutically acceptable salt thereof, wherein ring B, L1, ring A, L2, n, R1, R2, R3, R4, and X1 are as described herein. Pharmaceutical compositions comprising the compound, as well as the methods of making and using the compound, are also provided.

MAP4K1 INHIBITORS

One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.

ISOQUINOLINE COMPOUNDS AND USES THEREOF

Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER

3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.

SMARCA INHIBITORS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/or polybromo-1 (PB-1) protein via ubiqitination and/or degradation by compounds. The compounds are useful in treatment of cancer.

DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activa

ISOQUINOLINES AS INHIBITORS OF HPK1

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.